Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study

By sjmartinez • July 13, 2024

Narasaki Y, Kovesdy CP, You AS, Sumida K, Mallisetty Y, Surbhi S, Thomas F, Amin AN, Streja E, Kalantar-Zadeh K, Rhee CM. Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study. Lancet Reg Health Am. 2024 Jun 18;36:100814. doi: 10.1016/j.lana.2024.100814. PMID: 38993538; PMCID: PMC11237921.

Tags: Harbor UCLA, Nephrology, Publications, Veterans Administration

Pulmonary Rehabilitation Prolongs Life…And May Be Dying

Mosher CL, Casaburi R. Pulmonary Rehabilitation Prolongs Life…And May Be Dying. Am J Respir Crit Care Med. 2026 Apr 7:aamag168. doi: 10.1093/ajrccm/aamag168. Epub ahead of[...]

Association of Polygenic Risk Scores With Aortic Valve Calcium: The Multi-Ethnic Study of Atherosclerosis

Whelton SP, Yao J, Clish C, Wood AC, Taylor KD, Blaha MJ, Budoff M, Marrero N, Thanassoulis G, Post WS, Guo X, Rotter JI. Association[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]